- Home
- MBOT vs ZNTL Comparison
MBOT vs ZNTL Comparison
Compare MBOT & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MBOT | ZNTL |
|---|---|---|
| Founded | 2010 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.3M | 118.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | MBOT | ZNTL |
|---|---|---|
| Price | $2.22 | $1.40 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $8.75 | $5.87 |
| AVG Volume (30 Days) | ★ 3.0M | 494.2K |
| Earning Date | 11-12-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $26,865,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2,166.67 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.93 | $1.01 |
| 52 Week High | $4.67 | $3.53 |
Technical Indicators
Market Signals| Indicator | MBOT | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 46.82 | 49.62 |
| Support Level | $2.31 | $1.34 |
| Resistance Level | $2.55 | $1.48 |
| Average True Range (ATR) | 0.17 | 0.06 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 52.11 | 55.88 |
Price Performance
Historical ComparisonAbout MBOT Microbot Medical Inc.
Microbot Medical Inc is a breakthrough medical device company. The group is focused on transforming endovascular procedures through advanced robotic technology. Microbot's LIBERTY Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency and provider safety. With a robust intellectual property portfolio and a deep commitment to innovation, Microbot is shaping the future of endovascular care.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.